These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11199608)

  • 1. New drug approvals in 1999.
    Wynn RL
    Gen Dent; 2000; 48(4):380-4. PubMed ID: 11199608
    [No Abstract]   [Full Text] [Related]  

  • 2. New use approved for Vioxx.
    FDA Consum; 2002; 36(4):3. PubMed ID: 12184302
    [No Abstract]   [Full Text] [Related]  

  • 3. The pain game.
    Wadman M
    Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract]   [Full Text] [Related]  

  • 4. What ails the FDA?
    Cohen FJ
    N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962406
    [No Abstract]   [Full Text] [Related]  

  • 5. New drug approvals in 2001.
    Wynn RL
    Gen Dent; 2002; 50(4):304-8, 310. PubMed ID: 12640845
    [No Abstract]   [Full Text] [Related]  

  • 6. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 8. [New indication for selective COX-2 inhibitors. Now also approve for acute pain].
    MMW Fortschr Med; 2002 Mar; 144(10):62. PubMed ID: 11928272
    [No Abstract]   [Full Text] [Related]  

  • 9. [Already the drug of choices in the USA. Coxibe in joint pain].
    MMW Fortschr Med; 2002 Aug; 144(31-32):53. PubMed ID: 12422738
    [No Abstract]   [Full Text] [Related]  

  • 10. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 11. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
    Vanchieri C
    J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
    Epstein RA
    Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
    [No Abstract]   [Full Text] [Related]  

  • 13. New drugs and product approvals from 2001.
    Taylor SE
    Tex Dent J; 2002 Dec; 119(12):1186-98. PubMed ID: 12592740
    [No Abstract]   [Full Text] [Related]  

  • 14. The COX-2 inhibitors--an update.
    Furberg CD
    Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effective not only in rheumatism and arthrosis. Rofecoxib fights also acute pain].
    MMW Fortschr Med; 2002 Feb; 144(7):68. PubMed ID: 11887740
    [No Abstract]   [Full Text] [Related]  

  • 16. Non-steroidal anti-inflammatory drugs in orofacial pain management--an update.
    van der Bijl P; van der Bijl P
    SADJ; 2002 Aug; 57(8):328-31. PubMed ID: 12428528
    [No Abstract]   [Full Text] [Related]  

  • 17. [Really only Vioxx?].
    Heinzl S
    Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
    [No Abstract]   [Full Text] [Related]  

  • 18. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 19. Withdrawal syndrome.
    Nat Med; 2004 Nov; 10(11):1143. PubMed ID: 15516887
    [No Abstract]   [Full Text] [Related]  

  • 20. The Vioxx debacle revisited.
    Good CB; Kelley CL
    Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.